Karen Luong

Karen is the co-founder and co-lead of the firm’s Psychedelic and Emerging Therapies practice group. This groundbreaking group guides researchers, manufacturers, investors, clinicians and other participants around and through the myriad obstacles that result from the patchwork of state and federal laws regulating Schedule I controlled substances.

In addition to Karen’s focus on psychedelic law and complex products liability, she also has experience representing clients in general commercial litigation, business litigation and the cannabis industry.